{
    "title": "110_s2274",
    "content": "The Act titled \"Dextromethorphan Abuse Reduction Act of 2007\" is cited as the short title. Key findings are outlined in Section 2. Congress finds that cough medicines containing dextromethorphan, when abused at high doses, can lead to dangerous effects such as hallucinations, rapid heart beat, and seizures. The accessibility and low cost of dextromethorphan have contributed to increased abuse, especially among teenagers. Abuse of this drug can result in psychological dependence, impaired judgment, and potential injury or death. Dextromethorphan abuse has increased significantly, especially among children aged 9 to 17 years. In 2005, an estimated 2,400,000 teenagers abused over-the-counter cough medicines. The Food and Drug Administration considers dextromethorphan abuse a serious issue that can lead to death and other adverse effects. Retailers have implemented age restrictions on cough medicine purchases in response to this trend. Prevention is crucial in addressing the increase in dextromethorphan abuse. Education campaigns for teens and parents about the dangers of these drugs play a significant role in this effort. SEC. 3. DEXTROMETHORPHAN. The term 'finished dosage form' for dextromethorphan refers to the drug in a retail-ready tablet, capsule, solution, or liquid form with inactive ingredients, approved as a nonprescription drug under the Federal Food, Drug, and Cosmetic Act. It can also include dextromethorphan combined with other ingredients during manufacturing. The term 'unfinished' dextromethorphan refers to any concentration or amount of the drug that is not in finished dosage form. Schedule V of the Controlled Substances Act is amended to include 'Unfinished dextromethorphan'. Additionally, sales of dextromethorphan in finished dosage form are regulated under Part D of the Controlled Substances Act. \"Civil penalties for certain dextromethorphan sales are outlined in Section 424.\" \"It is unlawful to sell dextromethorphan to individuals under 18 years old, including online sales. Failure to check ID is considered knowledge of the buyer's age. An affirmative defense is available for alleged violations.\" The Attorney General may impose a civil penalty on a person for violating the sale of dextromethorphan to individuals under 18 years old, unless a valid prescription is presented. An affirmative defense is available if the seller checked the purchaser's ID and reasonably concluded they were at least 18 years old. The civil penalties for violating the sale of dextromethorphan to individuals under 18 years old are as follows: $1,000 for the first violation, $2,000 for the second violation, and $5,000 for the third violation or subsequent violations. Each location where sales occur is considered a separate entity for determining violations. The term \"identification card\" refers to an ID that meets specific criteria. An identification card meeting specific criteria, including a photo and date of birth, issued by a State or Federal Government, and acceptable for certain regulations. The Attorney General must regulate Internet sales of dextromethorphan products within 180 days to comply with the Controlled Substances Act. The Attorney General must regulate fines for violations of the Controlled Substances Act within 180 days of enactment, based on prior offenses by a retailer or its employees. The Attorney General must regulate fines for violations of the Controlled Substances Act within 180 days of enactment, based on prior offenses by a retailer or its employees. The fines may be reduced or eliminated for retailers with effective employee training programs or other compliance actions. The Act requires retailers to comply with regulations regarding products containing dextromethorphan. Retailer is defined as grocery, general merchandise, drug, or convenience stores primarily selling for personal use. The Senate emphasizes manufacturers' responsibilities. Manufacturers of products containing dextromethorphan should include warnings on packages about misuse, and retailers should implement safeguards against theft. The Director of National Drug Control Policy will provide funding to the Partnership for a Drug-Free America for education on preventing drug abuse among individuals under 18 and parents. The Director of National Drug Control Policy will provide funding to the Community Anti-Drug Coalition of America for education and training on preventing the abuse of prescription and nonprescription drugs, including dextromethorphan. $4,000,000 is authorized to be appropriated for each fiscal year from 2008 to 2010 for this purpose. Authorization of $4,000,000 for fiscal years 2008-2010 to supplement grant funds for drug abuse prevention activities. Definitions provided for \"Administrator\" and \"drug\" in this subsection. The term \"eligible entity\" refers to an organization that has received a grant under the Drug-Free Communities Act of 1997 and has documented rates of drug abuse above national averages using local data. The Administrator may provide enhancement grants to eligible entities for implementing strategies addressing prescription and nonprescription drug abuse. Eligible entities must submit an application for the grant. Entities eligible for an enhancement grant must submit an application to the Administrator with a detailed plan to address drug abuse. Grant funds are to be used for implementing a community-wide strategy in accordance with the submitted plan. Grant terms under this subsection include a maximum period of 4 years and a limit of $50,000 per year. Funds must supplement, not replace, other available funds. Evaluation requirements are the same as those for grants under the Drug-Free Communities Act of 1997. Administrative expenses are capped at 6 percent. Authorization of appropriations is set at $4,000,000 annually for fiscal years 2008 through 2010. Data collection should include questions on drug abuse trends. Technical amendments to the Controlled Substances Act are made. The table of contents for the Comprehensive Drug Abuse Prevention and Control Act of 1970 is amended by redesignating paragraph (3) as paragraph (2). \"Sec. 424. Dextromethorphan sales.\""
}